Advanced Search
Current and Breaking News for Professionals, Consumers and Media



Click here to learn how to advertise on this site and for ad rates.

Cancer Issues Author: Staff Editor Last Updated: Nov 29, 2012 - 7:11:02 AM



Aspirin May Decrease Risk of Aggressive Form of Ovarian Cancer

By Staff Editor
Oct 9, 2012 - 8:22:24 AM



Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon Sign up for our Ezine
For Email Marketing you can trust


Email this article
 Printer friendly page
(HealthNewsDigest.com) - New research shows that women who regularly use pain relief medications, particularly aspirin, have a decreased risk of serous ovarian cancer—an aggressive carcinoma affecting the surface of the ovary. The study published in Acta Obstetricia et Gynecologica Scandinavica, a journal of the Nordic Federation of Societies of Obstetrics and Gynecology, reports that non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs), paracetamol (acetaminophen), or other analgesics did not decrease ovarian cancer risk.

Ovarian cancer is the deadliest gynecological malignancy and the fifth-leading cause of death by cancer for women in developed countries. Previous studies report that Denmark has one of the highest incidence and mortality rates at 11 and 7 per 100,000 women, respectively. According to the Centers for Disease Control and Prevention (CDC), each year 20,000 women in the U.S. are diagnosed with ovarian cancer, with 90% of cases occurring in women older than 40 years of age and the greatest number in those 60 years or older.

“Ovarian cancer has a high mortality. Understanding what factors are involved in the development of this disease and investigating preventative interventions for women are vitally important,” said lead author Dr. Susanne Kjær with the Danish Cancer Society Research Center. “Our study examined the role of analgesics in development of ovarian cancer.”

For the present study, researchers used data from the malignant ovarian cancer (MALOVA) study, a population-based, case-control study investigating this cancer in Danish women between 1995 and 1999. The team analyzed data from 756 women with epithelial ovarian cancer, classified by type of glandular tumors (adenocarcinomas); 447 were serous, 138 were mucinous, and 171 were other types. A random sample of 1564 women between the ages of 35 and 79 were drawn from the general population as controls. Personal interviews were conducted to determine analgesic drug use.

Findings indicate that women taking aspirin on a regular basis decreased their risk of serous ovarian cancer (odds ratio, OR=.60). Researchers did not find a decrease in ovarian cancer risk in women who regularly used non-aspirin NSAIDs, acetaminophen, or other types of pain relievers.

Dr. Kjær concludes, “Our findings suggest a potential protective effect of analgesic use on ovarian cancer risk, but that benefit should be balanced against adverse effects of pain medication use, such as risk of bleeding and peptic ulcers." The authors recommend that larger studies, which accurately assess dosage, frequency and duration of pain medications, are necessary to understand the impact of analgesic use on ovarian cancer.

In his editorial, also published in this month’s issue, Dr. Magnus Westgren from Karolinska University Hospital in Stockholm, Sweden concurs with the study authors that strategies for preventing ovarian cancer are imperative. Dr. Westgren discusses preventive procedures such as bilateral salingectomy (BSE)—a removal of the fallopian tubes—in women at risk for ovarian cancer.

“If we informed women about the possibility of performing BSE at repeat cesarean section for ovarian cancer prevention, it is likely that many women would opt for this procedure,” writes Dr. Westgren. He suggests that gynecology professionals discuss changing policies and setting up randomized trials to further understand how BSE could reduce ovarian cancer risk.

This study is published in Acta Obstetricia et Gynecologica Scandinavica. Media wishing to receive a PDF of this article may contact [email protected]
Full citation: “Use of Analgesic Drugs and Risk Of Ovarian Cancer: Results from a Danish Case–Control Study.” Henriette B. Ammundsen, Mette T. Faber, Allan Jensen, Estrid Høgdall, Jan Blaakær, Claus Høgdall and Susanne K. Kjær. Acta Obstetricia et Gynecologica Scandinavica; Published online: August 15, 2012 (DOI: 10.1111/j.1600-0412.2012.01472.x).
URL: http://doi.wiley.com/10.1111/j.1600-0412.2012.01472.x

“Editorial: “Prevention of Ovarian cancer – Let’s Do Something.” Magnus Westgren. Acta Obstetricia et Gynecologica Scandinavica; Published online: August 15, 2012 (DOI:10.1111/j.1600-0412.2012.01484.x).
URL: http://doi.wiley.com/10.1111/j.1600-0412.2012.01484.x

About the Journal:
Acta Obstetricia et Gynecologica Scandinavica is the official scientific journal of the Nordic Federation of Societies of Obstetrics and Gynecology (NFOG). It is a clinically oriented journal that covers all aspects of obstetrics, gynecology and reproductive health, including perinatology, gynecologic endocrinology, female urology and gynecologic oncology. The journal is published in English and includes: editors´ messages, editorials, Acta commentaries, Acta reviews and original articles under the main categories of investigation, pregnancy, birth, fertility, infection, gynecology, gynecologic urology, oncology and surgery. The journal is published by Wiley on behalf of the The journal is published by Wiley on behalf of the NFOG. For more information, please visit http://wileyonlinelibrary.com/journal/aogs.

About Wiley
Founded in 1807, John Wiley & Sons, Inc. has been a valued source of information and understanding for more than 200 years, helping people around the world meet their needs and fulfill their aspirations. Wiley and its acquired companies have published the works of more than 450 Nobel laureates in all categories: Literature, Economics, Physiology or Medicine, Physics, Chemistry, and Peace.
Wiley is a global provider of content and content-enabled workflow solutions in areas of scientific, technical, medical, and scholarly research; professional development; and education. Our core businesses produce scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising; professional books, subscription products, certification and training services and online applications; and education content and services including integrated online teaching and learning resources for undergraduate and graduate students and lifelong learners. Wiley's global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia. The Company's Web site can be accessed at http://www.wiley.com. The Company is listed on the New York Stock Exchange under the symbols JWa and JWb.

###

For advertising and promotion on HealthNewsDigest.com please contact Mike McCurdy: [email protected] or 877-634-9180
HealthNewsDigest.com is syndicated worldwide, to thousands of journalists in all media, and health-related websites. www.HealthNewsDigest.com

Top of Page

HealthNewsDigest.com

Cancer Issues
Latest Headlines


+ UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients
+ Aggressive Tumors Silence Genes that Fight Cancer
+ Cancer and Game Theory
+ Pancreatic Surgery Complications Impact Hospital Costs More Than Length of Stay
+ Depressed Men with Prostate Cancer are Diagnosed with Later Stage Disease Don’t Live as Long as Men who are Not Depressed
+ Advances in Treating Children with Cancer: The CWPW Pediatric Solid Tumor Program
+ Breast Cancer—Men Get It Too
+ New Future for Prostate Cancer
+ Low Dose of Targeted Drug Might Improve Cancer-Killing Virus Therapy
+ Targeted Patient Outreach Can Improve Colon Cancer Screening Rates



Contact Us | Job Listings | Help | Site Map | About Us
Advertising Information | HND Press Release | Submit Information | Disclaimer

Site hosted by Sanchez Productions